FEDERAL COURT OF AUSTRALIA
Pfizer Ireland Pharmaceuticals v Samsung Bioepis Au Pty Ltd [2017] FCA 573
File number: NSD 532 of 2017 Judge: NICHOLAS J Date of judgment: 24 May 2017 Catchwords: PRACTICE AND PROCEDURE – whether extension of time within which to apply for leave to appeal should be granted – where modest delay – where respondent did not assert application for leave to appeal was untenable Legislation: Federal Court Rules 2011 (Cth) r 35.14 Cases cited: AHC16 v Minister for Immigration and Border Protection [2017] FCA 152
Décor Corporation Pty Ltd v Dart Industries Inc (1991) 33 FCR 397
FAI General Insurance Company Limited v Southern Cross Exploration NL (1988) 165 CLR 268
Gallo v Dawson (1990) 93 ALR 479
Hunter Valley Developments Pty Ltd v Minister for Home Affairs and Environment (1984) 3 FCR 344
Mehmood v Attorney-General of the Commonwealth [2013] FCA 406
Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285
Date of hearing: 24 May 2017 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 13 Counsel for the Applicants: Mr D Shavin QC with Ms CL Cochrane Solicitor for the Applicants: DLA Piper Counsel for the Respondent: Mr DK Catterns QC with Mr D Larish Solicitor for the Respondent: Ashurst ORDERS
NSD 532 of 2017 BETWEEN: PFIZER IRELAND PHARMACEUTICALS
First Applicant
WYETH LLC
Second Applicant
PFIZER AUSTRALIA PTY LTD
Third Applicant
AND: SAMSUNG BIOEPIS AU PTY LTD ACN 611 890 094
Respondent
JUDGE:
NICHOLAS J
DATE OF ORDER:
24 MAY 2017
THE COURT ORDERS THAT:
1.The time for the applicants to file an application for leave to appeal be extended to 10 April 2017.
2.The costs of the applicants’ application for an extension of time be costs in the application for leave to appeal or, if leave to appeal is granted, in the appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
(Revised from Transcript)NICHOLAS J:
Before me is an application made by the applicants seeking an extension of time within which to seek leave to appeal against an order made on 21 March 2017 dismissing their application for preliminary discovery (see Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285). In accordance with r 35.13 of the Federal Court Rules 2011 (Cth) (“the FCRs”) the application for leave to appeal was required to be filed within 14 days after the order for dismissal was made, ie. by 4 April 2017. Instead, the present application, together with a number of affidavits in support, was filed and served on 10 April 2017, ie. six days, or four business days, later.
Rule 35.14(3) of the FCRs provides that an application for an extension of time must be accompanied by:
(a)the judgment or order from which leave to appeal is sought;
(b)the reasons for…
Keep reading for free
Create a free CaseChat account to read Pfizer Ireland Pharmaceuticals v Samsung Bioepis Au Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2017] FCA 573
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the court was whether the applicants should be granted an extension of time within which to apply for leave to appeal. The applicants had missed the deadline for filing their application for leave to appeal and sought an extension on the grounds that the delay was modest and the respondent had not asserted that the application for leave to appeal was untenable. The court had to consider the principles of law and the relevant rules of court in deciding whether to grant the extension.
The court considered the relevant case law and the provisions of the Federal Court Rules 2011. It noted that the court has discretion to extend the time for filing an application for leave to appeal, but that such extensions should be granted sparingly. The court found that the delay in this case was modest and that the respondent had not asserted that the application for leave to appeal was untenable. The court also noted that there were compelling reasons for the delay, including the applicants' belief that the appeal had no prospects of success. The court concluded that an extension of time should be granted and set the deadline for filing the application for leave to appeal as 10 April 2017.
The court further ordered that the costs of the applicants' application for an extension of time be costs in the application for leave to appeal or, if leave to appeal is granted, in the appeal. This means that if the applicants are successful in their appeal, the costs of the application for an extension of time will be included in the overall costs of the appeal. The court's decision provides guidance on the principles that the court will consider when deciding whether to grant an extension of time for filing an application for leave to appeal.
Orders
Orders of the court
1. The time for the applicants to file an application for leave to appeal be extended to 10 April 2017.
2. The costs of the applicants’ application for an extension of time be costs in the application for leave to appeal or, if leave to appeal is granted, in the appeal.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi